AU2001279294A1 - Melanin concentrating hormone receptor ligands - Google Patents

Melanin concentrating hormone receptor ligands

Info

Publication number
AU2001279294A1
AU2001279294A1 AU2001279294A AU7929401A AU2001279294A1 AU 2001279294 A1 AU2001279294 A1 AU 2001279294A1 AU 2001279294 A AU2001279294 A AU 2001279294A AU 7929401 A AU7929401 A AU 7929401A AU 2001279294 A1 AU2001279294 A1 AU 2001279294A1
Authority
AU
Australia
Prior art keywords
hormone receptor
receptor ligands
concentrating hormone
melanin concentrating
melanin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001279294A
Other languages
English (en)
Inventor
Rajagopal Bakthavatchalam
Alan Hutchison
Andrew Thurkauf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of AU2001279294A1 publication Critical patent/AU2001279294A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2001279294A 2000-07-06 2001-07-06 Melanin concentrating hormone receptor ligands Abandoned AU2001279294A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21608100P 2000-07-06 2000-07-06
US60/216,081 2000-07-06
PCT/US2001/041289 WO2002004433A2 (en) 2000-07-06 2001-07-06 Melanin concentrating hormone receptor ligands

Publications (1)

Publication Number Publication Date
AU2001279294A1 true AU2001279294A1 (en) 2002-01-21

Family

ID=22805607

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001279294A Abandoned AU2001279294A1 (en) 2000-07-06 2001-07-06 Melanin concentrating hormone receptor ligands

Country Status (7)

Country Link
US (3) US6569861B2 (ja)
EP (1) EP1366030A2 (ja)
JP (1) JP2004516239A (ja)
AU (1) AU2001279294A1 (ja)
CA (1) CA2414198A1 (ja)
MX (1) MXPA03000174A (ja)
WO (1) WO2002004433A2 (ja)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569861B2 (en) * 2000-07-06 2003-05-27 Neurogen Corporation Melanin concentrating hormone receptor ligands
AU2002305323A1 (en) 2001-05-04 2002-11-18 Tularik Inc. Fused heterocyclic compounds
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
IL158941A0 (en) 2001-05-22 2004-05-12 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
EP1425029A4 (en) * 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
EP1450801A4 (en) * 2001-11-27 2010-10-27 Merck Sharp & Dohme 2-AMINOQUINOLINE COMPOUNDS
EP1451156A4 (en) * 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOQUINOLINE COMPOUNDS
WO2003060475A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
EP1465888A2 (en) 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
DE10233817A1 (de) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10250708A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
CN1330651C (zh) * 2002-11-06 2007-08-08 安姆根有限公司 稠合杂环化合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7727998B2 (en) * 2003-02-10 2010-06-01 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
WO2004081005A1 (en) * 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7067509B2 (en) * 2003-03-07 2006-06-27 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
CN1812985A (zh) * 2003-06-30 2006-08-02 先灵公司 治疗肥胖症的mch拮抗剂
CA2533112A1 (en) * 2003-08-13 2005-03-03 Christopher Hulme Melanin concentrating hormone receptor antagonist
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US20080044353A1 (en) * 2004-03-31 2008-02-21 Krause James E Combination Therapy for Weight Management
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7253168B2 (en) * 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
US20050239791A1 (en) * 2004-04-07 2005-10-27 Hutchison Alan J Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
US20050239826A1 (en) * 2004-04-14 2005-10-27 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7524862B2 (en) * 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004017930A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20050245529A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US20050267120A1 (en) * 2004-04-14 2005-12-01 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
AU2005296124A1 (en) * 2004-10-13 2006-04-27 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
EP2127676A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
DE602006017712D1 (de) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd Phenylpyridonderivat
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
BRPI0617621A2 (pt) 2005-10-21 2011-08-02 Novartis Ag combinação de compostos orgánicos
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
KR101318127B1 (ko) 2005-11-10 2013-10-16 엠에스디 가부시키가이샤 아자 치환된 스피로 유도체
RU2449989C2 (ru) 2006-06-23 2012-05-10 Эбботт Лэборетриз Производные циклопропиламина в качестве модуляторов h3-гистаминового рецептора
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US7606070B2 (en) * 2006-12-29 2009-10-20 Sandisk Corporation Systems for margined neighbor reading for non-volatile memory read operations including coupling compensation
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2155643B1 (en) 2007-06-08 2016-08-10 MannKind Corporation Ire-1a inhibitors
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
PE20110852A1 (es) 2008-10-30 2011-11-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
US9840512B2 (en) 2013-02-22 2017-12-12 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
CN113302189A (zh) 2018-11-20 2021-08-24 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
EP3924058A1 (en) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CN116249697A (zh) 2020-08-18 2023-06-09 默沙东有限责任公司 二环庚烷吡咯烷食欲素受体激动剂

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845058A (en) 1970-07-20 1974-10-29 R Viterbo N-(3,4-dihydro naphthyl)-n'phenyl piperazines
CH643549A5 (de) 1979-08-25 1984-06-15 Merz & Co N-(trimethoxybenzyl)-n'-phenylpiperazine.
FR2573075B1 (fr) 1984-09-14 1987-03-20 Innothera Lab Sa Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique
DE3582728D1 (de) 1985-01-17 1991-06-06 Ici Plc Tertiaere aminoverbindungen.
ES8605254A1 (es) 1985-11-30 1986-03-16 Servicios Y Suministros Farmac Procedimiento de obtencion de n-cinamilpiperazinas-n'-subs- tituidas
JPH0686438B2 (ja) 1989-03-27 1994-11-02 三菱化成株式会社 アミノベンゼンスルホン酸誘導体
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5225325A (en) 1990-03-02 1993-07-06 Ventana Medical Systems, Inc. Immunohistochemical staining method and reagents therefor
GB9100505D0 (en) * 1991-01-10 1991-02-20 Shell Int Research Piperidine derivatives
US5569659A (en) 1991-09-11 1996-10-29 Mcneilab, Inc. 4-arylpiperazines and 4-arylpiperidines
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
SK57097A3 (en) * 1994-11-07 1998-10-07 Pfizer Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
JP2941950B2 (ja) 1994-11-23 1999-08-30 ニューロゲン コーポレイション 或る種の４−アミノメチル−２−置換イミダゾール誘導体および２−アミノメチル−４−置換イミダゾール誘導体；新規な種類のドーパミン リセプタ亜型特異性リガンド
ATE294778T1 (de) 1995-01-23 2005-05-15 Daiichi Suntory Pharma Co Ltd Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
WO1997041108A1 (en) 1996-04-30 1997-11-06 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
HUP9601331A3 (en) 1996-05-17 2000-06-28 Egyt Gyogyszervegyeszeti Gyar Piperazine- and homopiperazine-derivatives, process for producing them and pharmaceutical compositions containing them
DE69731070T2 (de) * 1996-07-22 2005-03-17 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinol und arylpiperidin-derivate und sie enthaltende arzneimittel
WO1998003172A1 (fr) * 1996-07-22 1998-01-29 Suntory Limited Derives arylpiperidinol et arylpiperidine et medicaments les contenant
ES2197354T3 (es) * 1996-07-23 2004-01-01 Neurogen Corporation Derivados de bencilamina sustituidos con amido y amino; una nueva clase de ligandos especificos del neuropeptido y1.
CA2261031A1 (en) * 1996-07-23 1998-01-29 Charles A. Blum Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
CA2260982A1 (en) * 1996-07-23 1998-01-29 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
JP3329337B2 (ja) 1997-10-14 2002-09-30 三菱ウェルファーマ株式会社 ピペラジン化合物およびその医薬としての用途
US6284761B1 (en) 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
CA2383147A1 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Mch antagonists
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
DK1285651T3 (da) 2000-04-28 2010-12-13 Takeda Pharmaceutical Melanin-koncentrerende hormon-antagonister
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
EP1246847A2 (en) 2000-07-05 2002-10-09 Synaptic Pharmaceutical Corporation Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
JP2004504303A (ja) 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
US6569861B2 (en) * 2000-07-06 2003-05-27 Neurogen Corporation Melanin concentrating hormone receptor ligands
HUP0302582A2 (hu) 2000-12-22 2003-12-29 Schering Corp. Piperidin MCH antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk elhízás kezelésére

Also Published As

Publication number Publication date
US6569861B2 (en) 2003-05-27
JP2004516239A (ja) 2004-06-03
US20040229883A1 (en) 2004-11-18
MXPA03000174A (es) 2003-09-22
US7323478B2 (en) 2008-01-29
WO2002004433A3 (en) 2003-09-25
US6753336B2 (en) 2004-06-22
EP1366030A2 (en) 2003-12-03
US20020052383A1 (en) 2002-05-02
WO2002004433A2 (en) 2002-01-17
US20030191136A1 (en) 2003-10-09
CA2414198A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
AU2001279294A1 (en) Melanin concentrating hormone receptor ligands
AU7315700A (en) Melanin concentrating hormone antagonist
IL158941A0 (en) Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
AU6306100A (en) Improved passage-travelling device
AU1199600A (en) Estrogen receptor ligands
HUP0204109A3 (en) Oral preparations for diabetes
AU5095000A (en) Receptor interacting protein rip3
AU5319700A (en) Nicotine receptor ligands
AU5869100A (en) Melanin concentrating hormone receptor
AU2001239562A1 (en) Novel melanin concentrating hormone receptor
AU4781100A (en) Ip3 receptor ligands
AU2001240800A1 (en) Secure services
EP1189944A4 (en) G-PROTEIN COUPLED RECEPTOR AXOR16
AU2001288220A1 (en) Hyperglycosylated polypeptides
AU4352000A (en) Clasp-2 transmembrane proteins
AU2001223882A1 (en) Receptor
AU2001282521A1 (en) OCT preparations
AU2001275362A1 (en) Nuclear hormone receptors
AU5491900A (en) Glycoprotein hormone family member
AU3821800A (en) Auxiliary device for serving
GB9927215D0 (en) Hormone receptor expression
AU5120000A (en) Structural device
EP1201245A4 (en) FUNCTIONAL ORAL PREPARATIONS
AU5545400A (en) Estrogen receptor
AU720865C (en) Pouring aid